Abstract-The article describes the study of targeted chemotherapeutic intervention on solid tumors by means of ultrasound and doxorubicin or paclitaxel loaded perfluoropentane nanoemulsions. Nanodroplets of the emulsions accumulated in a tumor by passive targeting. Under the action of a tumor directed thera peutic ultrasound, the nanodroplets converted into vapor microbubbles. In vivo, the nanodroplets strongly retained the loaded drugs; yet, under ultrasound mediated vaporization they released the drugs into the tumor tissue, thereby implementing effective targeting into the tumor. The tumors subjected to this treatment regressed effectively; however, after some time they recurred. The recurring tumors were more resistant to the repeated therapy than the primary ones. At present, the causes of of the resistance development and methods for its elimination are unclear and they are under investigation.
INTRODUCTION
Present day chemotherapy is associated with severe side effects caused by the drug induced action on healthy tissues. In addition, in the process of che motherapy, cells often become resistant to an active chemotherapeutic agent or multiple resistant to a plethora of chemotherapeutic agents. The use of nanomedicine methods opens new lines of attack on the problem of systemic toxicity of anticancer drugs. The Achilles' heel of malignant tumors is the enhanced permeability of their blood vessels [1] . In blood vessels of healthy tissues, the endothelial cells form a dense packing and do not let objects larger than 7 nm pass. In contrast to them, blood vessels in tumor tissues have sizeable gaps between the endothelial cells; they allow extravasation (i.e., transfer from ves sels into surrounding tissues) of particles with sizes up to 750 nm and even larger [2] . This property is funda mental for the targeting of chemotherapeutic agents to a tumor, or so called passive targeting. Drugs are encapsulated in nanoparticles (Fig. 1 ) that cannot penetrate blood vessels of healthy tissues; however, they penetrate through inter endothelial gaps and accumulate in a tumor. Liposomes, micelles, nanoemulsions, and nanobubbles are examples of such nanocarriers of drugs. The dosage forms shown in Fig. 1 comprise polymeric micelles (small circles), nanodroplets (stars), and microbubbles (large circles); the micelles are formed by biodegradable block copol ymers (for example, poly(ethylene glycol) block poly(L lactide) (PEG PLLA) or poly(ethylene gly col) block poly(caprolactone) (PEG PCL)); the droplets and bubbles are formed by perfluorocarbon (for example, perfluoropentane (PFP) and are stabi lized by the same (or another) block copolymer. A lipophilic drug, for example, doxorubicin (DOX), is localized in micelle cores and on the surface of the nanodroplets or microbubbles. The inter endothelial junctions in blood vessels of healthy tissues do not allow extravasation of drug loaded micelles and nano droplets (marked with a cross). To the contrary, tumors are characterized by a defective vasculature with great gaps between the endothelial cells, which leads to the extravasation of drug loaded micelles and nanodroplets resulting in their accumulation in the tumor interstitium. If microbubbles are formed during injection, they remain in the blood circulation.
An alternative approach to targeting is to form car riers that respond to pH variations or physical stimuli and release drugs under the action of light or sound. The development of ultrasound responsive carriers is particularly attractive, since ultrasound has a number of significant advantages over other types of treatment: it can be directed to deep seated tumors, it has many controlled parameters that allow optimization of treatment, and it can be used simultaneously for imag ing and therapy.
A combination of the approaches described allows implementing double targeting-the passive one due to predominant carrier accumulation in the tumor and the active one due to a tumor directed physical stimu lus that releases the drug locally in the tumor. It is this approach that is used in works of the laboratory of the first author of this paper [3] [4] [5] [6] .
MATERIALS AND METHODS

Block Copolymers
The block copolymers used in this study were bought from Polymer Source Inc. (Montreal, Quebec, Canada). In the majority of the experiments, the PEG PLLA block copolymer had a total molecular weight of 9.700 dalton (Da), whereas the blocks weighed 5.000 Da and 4.700 Da, respectively. This copolymer was used in the in vitro experiments (unless otherwise specified). In the animal experiments pre sented below, we used the PEG PLLA copolymer with a total molecular weight of 4.000 Da; the weight of each respective block was 2.000 Da. In the in vitro experiments, we also used a PEG PCL copolymer with a total molecular weight of 4.600 Da; the blocks had a weight of 2.000 Da and 2600 Da, respectively.
Micellar Solutions and Loading of Chemotherapeutic Drugs into Micelles
Micellar solutions of the PEG PLLA and PEG PCL block copolymers were prepared by a solvent exchange technique, which is described in detail in previous articles [5, 6] ; the DOX was loaded into micelles in the course of preparation of the micelles themselves. The chemotherapeutic drug Genexol (Genexol PM, hereafter GPM) being a paclitaxel encapsulated in the PEG PLLA micelles was bought from the Samyang Corp. (Taejon, South Korea). A desired weight of the powder was dissolved in the PEG PLLA or PEG PCL micellar solution.
Formulations
The paclitaxel loaded nanoemulsions were pre pared as follows. The micellar encapsulated paclitaxel (GEN) was dissolved in the micelles formed by a 0.25% PEG PLLA solution in a phosphate buffer, and 1 vol % PFP was added to this solution. Next, the sam ples were sonicated by 20 kHz ultrasound in ice cold water until the entire amount of PFP was transferred into the emulsion. Hereafter, this formulation is called nbGEN.
The DOX loaded nanoemulsions were prepared by the technique described earlier [6, 7] . Briefly, the drug was first loaded into the PEG PLLA or PEG PCL micelles; after that, the PFP was added to the micellar solution and the mixture was sonicated as described above.
Particle Size Distribution
Size distribution of nanoparticles was measured by dynamic light scattering at a scattering angle of 165°u sing a Delsa Nano S instrument (Beckman Coulter, Osaka, Japan) equipped with a 658 nm laser and a temperature controller. The size distributions of the nanoparticles were typically bimodal as shown in Fig. 2 (the upper row) , where the size of the unloaded micelles (the upper row, a) was somewhat lower than that of the drug loaded micelles (the upper row, b).
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Micelles Nanodroplets Ultrasound Vapor microbubbles Fig. 1 . Schematic representation of the passive drug targeting through the defective vasculature of a tumor. The dosage forms com prise polymeric micelles (small circles), nanodroplets (stars), and vapor PFP microbubbles (large circles). The micelles are formed by biodegradable block copolymers (e.g., PEG PLLA or PEG PCL), and the nanodroplets and bubbles are formed by perfluorocarbon (e.g., PFP) stabilized by the same (or another) block copolymer. The nanodroplets are formed after the intro duction of PFP into a copolymer solution and emulsification of this system. Primary microbubbles (with micron diameters) are formed from nanodroplets under the action of hyperthermia or ultrasound, and large microbubbles appear due to coalescence of the primary microbubbles. A lipophilic chemotherapeutic drug, e.g., DOX or paclitaxel, is localized in the micelle cores and (or) on the surface of nanodroplets/microbubbles. The endothelial lining of the blood vessels in normal tissues does not allow extrava sation of drug loaded micelles or nano/microbubbles (marked by cross). On the contrary, tumors are characterized by a defective vasculature with large gaps between the endothelial cells, which leads to extravasation of drug loaded micelles and nanobubbles and results in their accumulation in the tumor interstitium. If large microbubbles are formed upon injection, they remain in blood circulation. The figure is taken from [5] .
